Arcus Biosciences annual total liabilities
2017
2018
2019
2020
2021
2022
2023
2024
2025
Arcus Biosciences Total Liabilities Growth & History (RCUS)
Arcus Biosciences's total liabilities was $508.0M for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $508.0M | −$157.0M | −23.61% |
| 2024 | 2024-12-31 | $665.0M | $32.0M | +5.06% |
| 2023 | 2023-12-31 | $633.0M | −$55.0M | −7.99% |
| 2022 | 2022-12-31 | $688.0M | −$62.4M | −8.32% |
| 2021 | 2021-12-31 | $750.4M | $480.5M | +177.96% |
| 2020 | 2020-12-31 | $270.0M | $230.7M | +587.55% |
| 2019 | 2019-12-31 | $39.3M | −$715,000 | −1.79% |
| 2018 | 2018-12-31 | $40.0M | $3.4M | +9.19% |
| 2017 | 2017-12-31 | $36.6M | — | — |
Arcus Biosciences quarterly total liabilities
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $460.0M | −$66.0M | −12.55% |
| Q1 2026 | 2026-03-31 | $473.0M | −$152.0M | −24.32% |
| Q4 2025 | 2025-12-31 | $508.0M | −$157.0M | −23.61% |
| Q3 2025 | 2025-09-30 | $538.0M | −$149.0M | −21.69% |
| Q2 2025 | 2025-06-30 | $526.0M | −$25.0M | −4.54% |
| Q1 2025 | 2025-03-31 | $625.0M | $39.0M | +6.66% |
| Q4 2024 | 2024-12-31 | $665.0M | $32.0M | +5.06% |
| Q3 2024 | 2024-09-30 | $687.0M | $16.0M | +2.38% |
| Q2 2024 | 2024-06-30 | $551.0M | −$103.0M | −15.75% |
| Q1 2024 | 2024-03-31 | $586.0M | −$68.0M | −10.40% |
| Q4 2023 | 2023-12-31 | $633.0M | −$55.0M | −7.99% |
| Q3 2023 | 2023-09-30 | $671.0M | −$24.1M | −3.47% |
| Q2 2023 | 2023-06-30 | $654.0M | −$75.4M | −10.34% |
| Q1 2023 | 2023-03-31 | $654.0M | −$92.8M | −12.43% |
| Q4 2022 | 2022-12-31 | $688.0M | −$62.4M | −8.32% |
| Q3 2022 | 2022-09-30 | $695.1M | $398.4M | +134.30% |
| Q2 2022 | 2022-06-30 | $729.4M | $435.2M | +147.91% |
| Q1 2022 | 2022-03-31 | $746.8M | $476.5M | +176.27% |
| Q4 2021 | 2021-12-31 | $750.4M | $480.5M | +177.96% |
| Q3 2021 | 2021-09-30 | $296.7M | $30.0M | +11.26% |
| Q2 2021 | 2021-06-30 | $294.2M | $241.5M | +458.51% |
| Q1 2021 | 2021-03-31 | $270.3M | $234.8M | +661.36% |
| Q4 2020 | 2020-12-31 | $270.0M | $230.7M | +587.55% |
| Q3 2020 | 2020-09-30 | $266.7M | $226.9M | +571.18% |
| Q2 2020 | 2020-06-30 | $52.7M | $10.4M | +24.45% |
| Q1 2020 | 2020-03-31 | $35.5M | −$1.5M | −3.94% |
| Q4 2019 | 2019-12-31 | $39.3M | −$715,000 | −1.79% |
| Q3 2019 | 2019-09-30 | $39.7M | −$1.9M | −4.50% |
| Q2 2019 | 2019-06-30 | $42.3M | $3.0M | +7.73% |
| Q1 2019 | 2019-03-31 | $37.0M | −$1.8M | −4.75% |
| Q4 2018 | 2018-12-31 | $40.0M | $3.4M | +9.19% |
| Q3 2018 | 2018-09-30 | $41.6M | — | — |
| Q2 2018 | 2018-06-30 | $39.3M | — | — |
| Q1 2018 | 2018-03-31 | $38.8M | — | — |
| Q4 2017 | 2017-12-31 | $36.6M | — | — |
Arcus Biosciences total liabilities trends
Over the last five fiscal years, Arcus Biosciences's total liabilities increased from $270.0M to $508.0M, a change of $238.0M. The latest reported quarter, Q2 2026, shows $460.0M.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗Community posts
Arcus sets $17.50 share price for $250 million equity financing
Arcus Biosciences ($RCUS) priced an underwritten public offering of 14,285,715 new common shares at $17.50 apiece, targeting approximately $250 million in gross proceeds. The company is selling all of the shares, so the financing would add ...
Arcus reports additional kidney-cancer data supporting casdatifan development
Arcus Biosciences ($RCUS) released additional results from the ARC-20 program evaluating casdatifan in kidney cancer. Across pooled monotherapy cohorts involving 121 heavily pretreated patients, median overall survival was 35 months, median ...
